WINNIPEG, Manitoba, March 21, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0)
(the "Company" or "3DS"), is pleased to announce clinical study results which confirm that based on a swab from the inside of a
patient’s cheek, its proprietary TeloView™ software platform has the ability to identify patients with Alzheimer’s disease
(“AD”) and, furthermore, distinguish between mild, moderate, and severe forms of the disease. The results of this confirmatory
study have been accepted for publication in the peer-reviewed Journal of Alzheimer’s Disease.
AD is the most common form of dementia affecting approximately five million Americans age 65 and older, as well
as an estimated 200,000 Americans under the age of 65 who are afflicted with early-onset AD. AD is clinically defined as a
progressive neurodegenerative disorder that involves cognitive impairment, memory loss, visual-spatial retrogression and language
impairment. AD is the fifth leading cause of death for people age 65 and older.
“Current diagnostic methods are not highly specific,” commented Dr. Sabine Mai, 3DS co-founder and principal
inventor. “In addition, AD is only confirmed postmortem pathologically. There is a significant need for an accurate, non-invasive
biomarker that can diagnose AD and indicate disease progression, and we believe TeloView™ has the potential to answer that
important call.”
In agreement with previous research, the current study demonstrated that TeloView™ software platform
clearly distinguished between AD and non-AD individuals, and between mild, moderate and severe AD, and is, therefore, a promising
candidate as a non-invasive AD biomarker and monitoring tool. The current confirmatory study involved a cohort of 44 age- and
gender-matched healthy non-caregiver controls and 44 AD study participants. 3D telomeric profiles of buccal cells of AD patients
and their non-AD controls were examined with participant information blinded to the analysis.
The Company is currently exploring opportunities to expand the scope of its AD related work with further
clinical studies and to fund that work through non-dilutive or independent financing arrangements, such as a joint venture.
About 3DS
3DS (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform
based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical
studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform
technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is
designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the
Company’s new website at http://www.3dsignatures.com.
Forward-Looking Information
This news release includes forward-looking statements that are subject to risks and uncertainties.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of
the Company to be materially different from the historical results or from any future results expressed or implied by such
forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking.
Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance and actual results or developments may differ materially from those in
forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results
expressed or implied by forward-looking information include, among other things: market demand; technological changes that
could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition;
existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and
regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the
Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of
infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in
laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such
statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not
assume any obligation to update any forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Hugh Rogers VP Corporate Finance 604-428-8842 investors@3dsignatures.com OR Stephen Kilmer Investor Relations 647-872-4849 stephen.kilmer@3dsignatures.com
